Clinical trial
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00416650 · Vanderbilt-Ingram Cancer Center, Other · Completed
Key facts
| NCT number | NCT00416650 |
|---|---|
| Title | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) in Patients With Advanced Bronchioalveolar Cell Lung Cancer. |
| Lead sponsor | Vanderbilt-Ingram Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 16 |
| Start date | Jul 1, 2002 |
| Primary completion | Oct 1, 2007 |
| Completion | Mar 1, 2013 |
| First posted | Dec 28, 2006 |
| Last update posted | Apr 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: